RepliCel Launches Testing of Dermal Injector Units
Initial units delivered and first phase of functional testing nearly complete
VANCOUVER, BC, CANADA - 25 May 2021 - RepliCel Life Sciences Inc. (TSX.V:RP) (OTCPK:REPCF) (FRA:P6P2) ('RepliCel' or the 'Company'), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it has received the first units of its dermal injector and is nearing completion of the preliminary phase of functional testing required to launch executing on the larger-scale production and testing plan.
'In our February update, we announced that manufacturing of RepliCel's initial batch of commercial-grade dermal injectors and related consumables was resuming and that, upon delivery of the first units, we would commence functional testing. I am pleased to report we have now entered this phase,' stated RepliCel President and CEO, R. Lee Buckler.